Background: Gastric cancer-related deaths are among the leading causes of cancer-related deaths. Clinical trials with targeted agents continue in the treatment of stomach cancer, with randomized trials of chemotherapy to prolong survival in the treatment of metastatic gastric cancer. Metastatic stomach cancer treatment is also becoming increasingly personalized to the characteristics of the patient and tumor as it is in breast cancer. Result: Trastuzumab has shown randomized trial (TOGA study) in c-erbB2 positive metastatic stomach and gastroesophageal junction adenocancer patients to prolong median survival.Immunohistochemically, the presence of cerbB2 positivity and scoring at the time of diagnosis or in the resection material suggests that patients, especially in the metastatic stage, is necessary. The grade (score) of Cebb2 positivity was more pronounced in adenocarcinomas especially located anatomically close to the gastroesophageal junction. Conclusion: In our study, it was aimed to reveal the relationship between the demographic characteristics of patients who are candidates for treatment and the level of cerbB2 positivity and anatomic localization, especially in the metastatic stage if stomach and thyroid cancer are considered to be a common condition in our region.
CITATION STYLE
Yılmaz, H. T. K., Ergen, S., Baydar, İ., Çarlıoğlu, A., & Kurt, A. (2019, January 10). Relatıonshıp between C-erb-B2 expressıon and other prognostıc factors in gastrıc cancer. Bangladesh Journal of Medical Science. Ibn Sina Trust. https://doi.org/10.3329/bjms.v18i1.39562
Mendeley helps you to discover research relevant for your work.